TW202003518A - 用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物 - Google Patents

用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物 Download PDF

Info

Publication number
TW202003518A
TW202003518A TW108106752A TW108106752A TW202003518A TW 202003518 A TW202003518 A TW 202003518A TW 108106752 A TW108106752 A TW 108106752A TW 108106752 A TW108106752 A TW 108106752A TW 202003518 A TW202003518 A TW 202003518A
Authority
TW
Taiwan
Prior art keywords
methyl
amino
purine
ethyl
benzyl
Prior art date
Application number
TW108106752A
Other languages
English (en)
Chinese (zh)
Inventor
湯瑪士 波斯欽格
卡羅拉 萊斯
宏 沈
貟紅英
莎賓 霍夫司
卡瑞娜 黑吉
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202003518A publication Critical patent/TW202003518A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW108106752A 2018-02-28 2019-02-27 用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物 TW202003518A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
WOPCT/CN2018/077501 2018-02-28

Publications (1)

Publication Number Publication Date
TW202003518A true TW202003518A (zh) 2020-01-16

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108106752A TW202003518A (zh) 2018-02-28 2019-02-27 用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物

Country Status (19)

Country Link
EP (1) EP3758707A1 (es)
JP (1) JP7089596B2 (es)
KR (1) KR20200128414A (es)
CN (1) CN111801100B (es)
AR (1) AR114419A1 (es)
AU (1) AU2019228654A1 (es)
BR (1) BR112020016509A2 (es)
CA (1) CA3091950A1 (es)
CL (1) CL2020002139A1 (es)
CO (1) CO2020010306A2 (es)
IL (1) IL276817A (es)
MA (1) MA52412A (es)
MX (1) MX2020008746A (es)
PE (1) PE20211456A1 (es)
PH (1) PH12020551343A1 (es)
RU (1) RU2020131012A (es)
SG (1) SG11202008291XA (es)
TW (1) TW202003518A (es)
WO (1) WO2019166432A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
WO2024013205A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
SG175796A1 (en) * 2009-05-21 2011-12-29 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
EP2491035B1 (en) * 2009-10-22 2017-08-30 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP5848761B2 (ja) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体
BR112013002940A2 (pt) * 2010-08-13 2019-09-24 Baylor Res Institute adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
DK3294740T3 (da) * 2015-05-08 2019-11-04 H Hoffmann La Roche Ag Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
SI3504210T1 (sl) 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo
AU2017326400B2 (en) * 2016-09-13 2023-03-30 F. Hoffmann-La Roche Ag Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor

Also Published As

Publication number Publication date
BR112020016509A2 (pt) 2020-12-15
RU2020131012A (ru) 2022-03-28
CN111801100A (zh) 2020-10-20
JP2021514972A (ja) 2021-06-17
PE20211456A1 (es) 2021-08-05
EP3758707A1 (en) 2021-01-06
MA52412A (fr) 2021-06-02
WO2019166432A1 (en) 2019-09-06
AR114419A1 (es) 2020-09-02
KR20200128414A (ko) 2020-11-12
AU2019228654A1 (en) 2020-09-03
CL2020002139A1 (es) 2021-01-04
SG11202008291XA (en) 2020-09-29
MX2020008746A (es) 2020-09-28
CO2020010306A2 (es) 2020-08-31
JP7089596B2 (ja) 2022-06-22
PH12020551343A1 (en) 2021-06-21
IL276817A (en) 2020-10-29
CN111801100B (zh) 2023-10-24
CA3091950A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
JP6688352B2 (ja) 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物
TW202003518A (zh) 用於肝癌之治療及預防之7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物
US10398706B2 (en) Heteroaryldiazepine derivatives as RSV inhibitors
EP3027614B1 (de) Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen
RU2751349C2 (ru) 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
CA2788155C (en) Polyheterocyclic compounds highly potent as hcv inhibitors
CA2774145C (en) Hcv protease inhibitors
DK2694510T3 (en) IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
BR112021002479A2 (pt) composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
WO2014128111A1 (de) 4-substituierte pyrrolo- und pyrazolo-diazepine
TW201026686A (en) Heterobicyclic carboxamides as inhibitors for kinases
CA3098335A1 (en) Antiproliferation compounds and uses thereof
TW201617317A (zh) 吡啶酮衍生物
CA3133300A1 (en) Benzodiazepine derivatives as rsv inhibitors
WO2016146602A1 (de) Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung
US20200268762A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
TW201736391A (zh) 作為人類鼻病毒抑制劑之炔基核苷類似物
WO2015193229A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
WO2023005894A1 (zh) 一种Wnt通路抑制剂化合物
TW202416959A (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯𠯤，其類似物及使用其之方法